Get the latest tech news
Alzheimer's Scientist Indicted For Allegedly Falsifying Data In $16 Million Scheme
"A federal grand jury has indicted an embattled Alzheimer's researcher for allegedly falsifying data to fraudulently obtain $16 million in federal research funding from the National Institutes of Health for the development of a controversial Alzheimer's drug and diagnostic test," writes Beth Mole vi...
Simufilam is a small-molecule drug that Cassava claims can restore the structure and function of a scaffolding protein in the brain of people with Alzheimer's, leading to slowed cognitive decline. The committee also concluded that Cassava's lead scientist on its Alzheimer's disease program, Lindsay Burns, who was a frequent co-author with Wang, also likely bears some responsibility for the misconduct. Further, in September 2022, the Food and Drug Administration conducted an inspection of the analytical work and techniques used by Wang to analyze blood and cerebrospinal fluid from patients in a simufilam trial.
Or read this on Slashdot
